Balaxi Pharmaceuticals Ltd vs Granules India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Balaxi Pharmaceuticals Ltd is ₹ 26.63 as of 30 Apr 15:30 . The P/E Ratio of Balaxi Pharmaceuticals Ltd changed from 13.8 on March 2021 to 14.1 on March 2025 . This represents a CAGR of 0.43% over 5 yearsThe P/E Ratio of Granules India Ltd changed from 13.7 on March 2021 to 23.5 on March 2025 . This represents a CAGR of 11.40% over 5 years The Market Cap of Balaxi Pharmaceuticals Ltd changed from ₹ 524.5 crore on March 2021 to ₹ 352.89 crore on March 2025 . This represents a CAGR of -7.62% over 5 yearsThe Market Cap of Granules India Ltd changed from ₹ 7511 crore on March 2021 to ₹ 11814 crore on March 2025 . This represents a CAGR of 9.48% over 5 years The revenue of Balaxi Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 72.64 crore. This represent the decline of -100% The revenue of Granules India Ltd for the Mar '26 is ₹ 1495 crore as compare to the Dec '25 revenue of ₹ 1384 crore. This represent the growth of 8.02% The ebitda of Balaxi Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 3.19 crore. This represent the decline of -100% The ebitda of Granules India Ltd for the Mar '26 is ₹ 376.79 crore as compare to the Dec '25 ebitda of ₹ 304.46 crore. This represent the growth of 23.76% The net profit of Balaxi Pharmaceuticals Ltd changed from ₹ 6.48 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Granules India Ltd changed from ₹ 134.65 crore to ₹ 201.57 crore over 8 quarters. This represents a CAGR of 22.35% The Dividend Payout of Balaxi Pharmaceuticals Ltd changed from 3.41 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe Dividend Payout of Granules India Ltd changed from 6.72 % on March 2021 to 11.39 % on March 2025 . This represents a CAGR of 11.13% over 5 years .

About Balaxi Pharmaceuticals Ltd

Balaxi Pharmaceuticals Limited was initially incorporated in the name of 'The Anandam Rubber Company Limited' on September 28, 1942.
The Company changed its name from 'The Anandam Rubber Company Limited' to 'Balaxi Ventures Limited' on August 08, 2017 and further changed to Balaxi Pharmaceuticals Limited in 2021.
Initially, the Company was incorporated with the object of running rubber and tea plantations and owns several plantations across South India. In year 1989 the company sold its entire plantations to meet the emerging business needs and started concentrating in Investments and trading.
The company previously was a investment company, but the company during the financial year 2018-19 has commenced the business of International Wholesale Trading of Pharmaceuticals, Builders Hardware and FMCG Products On 15 March 2017, Balaxi Overseas Private Limited (BOPL) entered into a Share Purchase Agreement (SPA) with the erstwhile promoters of Company (i.

About Granules India Ltd

Granules India Limited is a large-scale vertically integrated company founded in March, 1991 manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediate (PFI) and Finished Dosage (FD).
With a strong presence across all three vertical, the company has created a leadership position in the off-patent drugs segment along with ensuring a strong presence in first line of defense' products such as Paracetamol, Ibuprofen, Metformin and Guaifenesin.
Granules India is the preferred supplier for some of the world's leading pharma branded and generics companies. Granules Life Sciences Private Limited, based in Hyderabad, Telangana, is a wholly owned subsidiary of Granules India.
It significantly enhances the Company's finished dosage manufacturing capabilities, contributing an additional 10 billion dosage units annually.

FAQs for the comparison of Balaxi Pharmaceuticals Ltd and Granules India Ltd

Which company has a larger market capitalization, Balaxi Pharmaceuticals Ltd or Granules India Ltd?

Market cap of Balaxi Pharmaceuticals Ltd is 147 Cr while Market cap of Granules India Ltd is 17,327 Cr

What are the key factors driving the stock performance of Balaxi Pharmaceuticals Ltd and Granules India Ltd?

The stock performance of Balaxi Pharmaceuticals Ltd and Granules India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Balaxi Pharmaceuticals Ltd and Granules India Ltd?

As of May 3, 2026, the Balaxi Pharmaceuticals Ltd stock price is INR ₹26.63. On the other hand, Granules India Ltd stock price is INR ₹699.25.

How do dividend payouts of Balaxi Pharmaceuticals Ltd and Granules India Ltd compare?

To compare the dividend payouts of Balaxi Pharmaceuticals Ltd and Granules India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.